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 11 
Abstract. 12 
The incidence of whooping cough caused by Bordetella pertussis in many developed countries has 13 
risen dramatically in recent years. This has been linked to the use of an acellular pertussis vaccine. 14 
In addition, it is thought that B. pertussis is adapting under acellular vaccine mediated immune se-15 
lection pressure, towards vaccine escape. Genomics-based approaches have revolutionised the 16 
ability to resolve the fine structure of the global B. pertussis population and its evolution during the 17 
era of vaccination. Here, we discuss the current picture of B. pertussis evolution and diversity in 18 
the light of the current resurgence, highlight import questions raised by recent studies in this area 19 
and discuss the role that functional genomics can play in addressing current knowledge gaps. 20 
 21 
Resurgence of Pertussis. 22 
Whooping cough, or Pertussis, caused by infection by Bordetella pertussis, was once a major 23 
cause of infant deaths worldwide. The introduction of Pertussis vaccination during the 1940’s and 24 
1950’s in developed countries appeared to largely eradicate the disease in these countries. Per-25 
tussis remained a prominent infection in developing countries but since 1980, the percentage of 26 
the target population receiving at least one vaccination has risen from 30 to 90%, and the number 27 
of reported cases has fallen from nearly 2 million to approximately 161 500 per year in that time 28 
(WHO 2014). However, while a vast majority of developed countries switched from the use of 29 
whole cell Pertussis vaccines (WCV) to acellular (ACV) ones, developing countries continue to use 30 
WCV-based combination vaccines. 31 
 32 
It is thus of great concern that Pertussis appears resurgent in numerous countries despite high 33 
levels of vaccination. There is a strong link between the use of ACVs and resurgence, which has 34 
raised a number of important questions regarding vaccine efficacy and the ability of these vaccines 35 
to continue to control disease at the population level (Burns, et al. 2014: S32-S5). This is not only 36 
of concern to the developed countries using these vaccines, but world-wide as many other coun-37 
tries aspire to switch to ACVs due to their perceived better safety profile compared to WCV. 38 
 39 
ACVs comprise purified B. pertussis proteins, most contain filamentous haemagglutinin, pertussis 40 
toxin and pertactin while some also include fimbrial proteins (Fim2 and Fim3). ACVs were devel-41 
oped in response to concerns over reactions to vaccination with WCV.  Injection site soreness, irri-42 
tability and low grade fever were common sequelae while a syndrome termed Pertussis-vaccine 43 
encephalopathy was an association between WCV and serious neurological episodes (Cherry 44 
1992: 1033-8, Cherry 1996: S 259-S 63). Although, now largely disproved, at the time this associa-45 
tion was extremely damaging to public confidence in Pertussis vaccination. Compared to WCV, 46 
ACVs are considered much better tolerated (Cherry 1993: 21-4).  47 
 48 
However, it has been long-recognised that WCV and ACV induce immunity of different profiles 49 
even though clinical trials of ACVs established that they are as efficacious as WCV for the prime 50 
consideration of protecting young babies and infants from classic Pertussis disease, for example 51 
(Lugauer, et al. 2002: 142-6). However, it is now becoming evident that there are important differ-52 
ences in the duration of immunity induced by the two vaccines, with ACV-induced immunity waning 53 
earlier than that induced by WCV (Rendi-Wagner, et al. 2006: 5960-5, Witt, et al. 2012: 1730-5). 54 
These studies found a strong correlation between the use of ACV and a higher risk of infection in 55 
older children and adolescents. 56 
 57 
2 
Also there are clear differences between the T cell responses induced by WCV compared to ACV, 58 
being Th1/Th17-biased compared to Th2/Th17 biased respectively (Ross, et al. 2013: e1003264). 59 
The consequences of differences between ACV and WCV induced immunity have become clearer 60 
in a recent study in the recently developed infant baboon model of infection. This demonstrated 61 
that ACVs protect the individual from manifestations of serious disease but not from colonisation 62 
and that ACV-vaccinated, colonised baboons are able to transmit bacteria to naive animals 63 
(Warfel, et al. 2013). The strongest resistance to challenge with B. pertussis was observed for 64 
convalescent animals while baboons vaccinated with WCV became colonised but to a lower ex-65 
tent, and for a shorter period of time, than ACV vaccinated animals. The same skew in T cell re-66 
sponses to ACV were observed in baboons. 67 
 68 
Overall, there are clear differences in the type of immunity that ACVs induce compared to WCV, 69 
involving both B and T cell mediated immunity. The results of this are a shorter duration of immuni-70 
ty and a decrease in protection from infection with ACVs compared to WCV. Readers are referred 71 
to an excellent recent review for a detailed discussion of this (Warfel and Edwards 2015: 48-54). 72 
These data strongly suggest that the switch from WCV to ACV will have caused changes to the 73 
epidemiology of Pertussis in regions using ACV. Thus, it is likely that this has at least played a part 74 
in, if not caused, the resurgence of Pertussis experienced by many of these countries. 75 
 76 
It is plausible that a change in host immunity and overall epidemiology will have an effect on the B. 77 
pertussis population. It is argued that B. pertussis is evolving under the different immune-selection 78 
pressure induced by ACVs (Mooi 2010: 36-49, Mooi, et al. 2014: 685-94) and that pathogen adap-79 
tation towards escape from vaccine-mediated immunity is also part of the resurgence story. To this 80 
end, a number of studies have identified subtle genetic changes in B. pertussis isolates over time, 81 
consistent with this hypothesis (see below). However, definitive evidence for current B. pertussis 82 
strains having altered infection biology is lacking. In fact the current debate regarding possible 83 
causes of, and solutions to Pertussis resurgence has highlighted that understanding of B. pertussis 84 
infection biology has many critical knowledge gaps that will need to be filled to meet these aims. 85 
 86 
Much of our knowledge of B. pertussis virulence is based on a relatively small number of B. per-87 
tussis proteins. The advance of functional genomics means it is now feasible to study B. pertussis 88 
at a systems level, using genome-wide approaches that are unbiased compared to more traditional 89 
studies of individual proteins or genetic loci. Here we discuss the contribution of genomics anal-90 
yses to the current picture of B. pertussis adaptation, and how they might address the important 91 
questions arising during debate of resurgence. 92 
 93 
B. pertussis phylogeny in the pre-genomics era. 94 
The study of B. pertussis phylogeny in the pre-genomics era was hampered by the very low levels 95 
of variation between strains. B. pertussis lacks phenotypic characters with the variability to be used 96 
for differentiation, such as the surface antigens used for serotyping of many of other bacterial 97 
pathogens. 98 
 99 
PFGE. Pulse field gel electrophoresis has been used widely to differentiate between B. pertussis 100 
strains. It benefits from not requiring knowledge of particular bacterial components but suffers from 101 
difficulty in ensuring reproducibility between different labs and limited discriminatory power. How-102 
ever, from its use it was evident that B. pertussis isolates were divisible into different PFGE types, 103 
and that there was relatively limited diversity in the number of types observed given the seemingly 104 
large scope for variation, for example see (van Gent, et al. 2015: 821-30). It is not clear how many 105 
types arose by mutation of the restriction enzyme recognition sites or through intra-genome re-106 
combination and thus PFGE is unable to reveal information about the nature of differences be-107 
tween strains with different PFGE types. 108 
 109 
MVLA. Multiple-locus variable number tandem repeat analysis (MVLA) discriminates between 110 
strains based on variation in the number of repeats at distinct loci. These regions are amplified by 111 
PCR and the size of the amplicon used to determine the number of repeats at each locus within 112 
strains. Strains are assigned to a MLVA type according to their profile of repeat sizes. This ap-113 
proach has identified numerous different MLVA types, for example see (Kurniawan, et al. 2010: 114 
3 
297-300). It is high throughput allowing analysis of a large number of strains but suffers from it not 115 
being clear as to how, or how often, variation in repeats occur. Thus, a clone in which a particular 116 
repeat length changes will be assigned as a different MVLA type even though the remainder of the 117 
genome may be identical. Thus, it is not always apparent as to what the MLVA types of a collection 118 
of strains indicate about their relatedness. 119 
 120 
Allele typing. Many studies described strains as allele types, based on identification among 121 
strains of a limited number of alleles of the genes encoding a small number of key virulence fac-122 
tors, notably pertactin (prn), ptxA (encoding the enzymatically active subunit of pertussis toxin) and 123 
fimbrial subunits (fim) type 2 and 3. This was later expanded to include alleles of the promoter re-124 
gion of the pertussis toxin locus (ptxP). The profile of alleles of strains was used to assign them to 125 
a Sequence Type, for example see (Litt, et al. 2009: 680-8). However, the limited variation among 126 
B. pertussis meant that focusing on such a small portion of the genome represented by these few 127 
genes resulted in many strains appearing identical, with changes in Sequence Types being identi-128 
fied relatively infrequently. 129 
 130 
The ptxP3 allele has received particular attention. The SNP giving rise to this allele lies in a binding 131 
site for the transcriptional regulator BvgA and is thought to increase the affinity of BvgA for binding 132 
to the promoter and in doing so, increase the level of transcription of the associated pertussis toxin 133 
locus (Mooi, et al. 2009: 1206-13). Thus, strains carrying the ptxP3 allele secrete increased 134 
amounts of toxin compared to strains carrying other alleles and this has been proposed to increase 135 
transmission of ptxP3 strains, possibly through increasing the severity of clinical symptoms (Mooi, 136 
et al. 2009: 1206-13). Certainly the frequency of ptxP3 has increased dramatically since the mid 137 
1990’s such that a majority of current isolates in developed countries carry ptxP3 (Lam, et al. 2012: 138 
492-5). A recent study identified that both the SNP itself, and the genetic background of a ptxP3 139 
strain contributed to an increase in fitness in a mouse model of infection compared to a ptxP1 140 
strain (King, et al. 2013: e66150) supporting the hypothesis that ptxP3 strains represent a lineage 141 
with a fitness advantage over other strains, although the exact mechanism operating is not fully 142 
understood. 143 
 144 
Such studies revealed that new alleles or sequence types arose over time and often one allele ap-145 
peared to replace previously dominant alleles across the B. pertussis population, leading to the 146 
picture in which a particular clone appeared to dominate at any one time until replaced by a novel 147 
type, termed selective sweeps (van Gent, et al. 2012: e46407). These approaches were very valu-148 
able for tracing the replacement of clones and led to the realisation that the B. pertussis population 149 
changed over time. There is evidence from the case of the ptxP3 allele that some of these chang-150 
es may reflect changes in fitness of B. pertussis and as certain clonal sweeps coincided with 151 
changes to vaccine schedules or the switch from WCV to ACV, this raised the possibility that vac-152 
cination was a driver of B. pertussis evolution. 153 
 154 
However, the focus on very limited regions of the genome, in a bacterium with relatively low levels 155 
of mutation, meant that there was insufficient ability to discriminate between strains co-circulating 156 
in most populations to reveal the true picture of strain diversity of B. pertussis. 157 
 158 
 159 
Genomic analysis. 160 
Genomics has been hugely informative to the study of Bordetella, B. pertussis in particular. The 161 
original Bordetella genome project simultaneously sequenced the genomes of a representative 162 
strain of B. pertussis, B. parapertussis and B. bronchiseptica and revealed much about the specia-163 
tion of B. pertussis and B. parapertussis from B. bronchiseptica (or a B. bronchiseptica-like ances-164 
tor) (Parkhill, et al. 2003: 32-40), identifying that B. pertussis evolved as a species primarily by loss 165 
of DNA and intra-genomic recombination arising via recombination between IS element repeats, 166 
particularly IS481 (Parkhill, et al. 2003: 32-40). A notable feature of B. pertussis is the very high 167 
number of copies of these repeats, particularly IS481 that is present at around 250 copies per ge-168 
nome. IS1663 is present at around 30 copies. Such deletions have resulted in the genomes of B. 169 
pertussis being over a Mb smaller than those of B. bronchiseptica. On going recombination be-170 
tween IS element repeats is still shaping the B. pertussis genome (see below). 171 
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 172 
The monomorphic nature of B. pertussis has been taken as evidence that it arose very recently 173 
although its origin has been debated. There is no evidence in the ancient literature for the pres-174 
ence of classic whooping cough. Such references begin to appear in medieval Europe suggesting 175 
that classic whooping cough became established in Europe around the 14th or 15th century (Lapin 176 
1943), possibly via import from other regions. The expansion of IS elements in B. pertussis is sug-177 
gestive of a niche jump, as the fixation in the population of what would be ordinarily a highly delete-178 
rious level of genome disruption is indicative of a lack of competition from progenitor bacteria, typi-179 
cal of break through into a new niche (Preston, et al. 2004: 379-90). Wider analysis of the expan-180 
sion of IS elements in niche restricted bacteria point towards the specialisation of human-specific 181 
bacterial pathogens occurring during the Neolithic period (approximately 10 000 years ago) due to 182 
the advent of agriculture creating stable and larger human communities that are favourable envi-183 
ronments for bacteria to specialise (Mira, et al. 2006: 200-6). 184 
 185 
While this niche jump is suggestive of a recent introduction of the Bordetellae into humans, analy-186 
sis of B. bronchiseptica identified a distinct clade (Cluster IV) of seemingly human-associated B. 187 
bronchiseptica from which B. pertussis arose (Diavatopoulos, et al. 2005: e45). Thus, the genomic 188 
changes in B. pertussis likely represent the specialisation to a human-restricted niche, rather than 189 
the introduction into humans per se. It is unclear if this was concomitant with the evolution of the 190 
virulence represented by classic whooping cough, or if this was a later event arising from other ge-191 
nomic changes. For example, pertussis toxin appears important for virulence due to its subversive 192 
effect on immune cells. The genetic locus for PT and its secretion is present also in B. bronchisep-193 
tica and B. parapertussis, suggesting that it was present in the ancestor of B. pertussis. However, 194 
toxin expression is observed only in B. pertussis. While two mutations in toxin genes in B. paraper-195 
tussis may explain its lack of toxin production, the locus appears intact in B. bronchiseptica. The 196 
promoter for this locus is identical between B. bronchiseptica and B. parapertussis. While a num-197 
ber of ptxP alleles have been identified among B. pertussis, including ptxp3 (and see below), all 198 
contain several differences from the B. bronchiseptica promoter that likely enhance transcription of 199 
the locus by enhancing binding of BvgA (Parkhill, et al. 2003: 32-40). Thus, the B. pertussis pro-200 
moter directs toxin expression (or greatly enhanced expression) and increased virulence. Howev-201 
er, it is unclear whether these SNPs arose during speciation of B. pertussis or subsequent to this in 202 
a lineage that has likely displaced others, akin to the recent rise to dominance of ptxP3. 203 
 204 
Whatever the scenario, it is very likely that B. pertussis is a recently evolved lineage, highly 205 
adapted (and possibly still adapting) to the human host, with little genetic diversity among the 206 
global population, certainly compared to many other bacterial pathogens. Fascinatingly, a very 207 
similar scenario has occurred twice more, giving rise to B. parapertussis (Parkhill, et al. 2003: 32-208 
40) and B. holmesii (Harvill, et al. 2014). There is sparse information regarding these other two 209 
species. However, both have undergone IS element expansion in their genomes, both appear to 210 
have suffered genome reduction (likely a consequence of high numbers of IS repeats in the ge-211 
nomes) and both can cause Pertussis, or at least Pertussis-like disease. It is likely that compara-212 
tive studies of these three Bordetella will yield a fresh insight into the evolution of whooping cough. 213 
 214 
The availability of a reference B. pertussis genome sequence allowed further interrogation of B. 215 
pertussis diversity. Comparative genomic hybridisation using micro-arrays of numerous strains re-216 
vealed a largely highly conserved gene content (Bouchez, et al. 2008: e2437, Kallonen, et al. 217 
2011: 2034-42, King, et al. 2010: 64). Differences were largely due to the presence or absence of 218 
discrete regions, suggesting limited variability in IS element-derived deletions among strains. In 219 
general, recent strains contained more deletions than older strains suggesting that gene loss is on 220 
going in B. pertussis. 221 
 222 
More recently, next generation sequencing has provided a quantum leap in analysis of B. pertussis 223 
enabling whole genome sequences to be generated for multiple strains, and for them to be re-224 
solved at single base resolution. Two recent studies in particular have highlighted the insights pos-225 
sible with this approach. A landmark study by Bart and colleagues generated and analysed ge-226 
nome sequences from 343 strains isolated over many decades from across the globe providing the 227 
definitive view of B. pertussis diversity and evolution over recent times (Bart, et al. 2013). 228 
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 229 
The limited genetic diversity of B. pertussis was confirmed with just 5 414 SNPs identified among 230 
all of the strains analysed. This allowed calculation of a mutation rate of 2.24 x 10-7 per site per 231 
year and an average SNP density of 0.0013 SNPs/bp. Interestingly, phylogenetic analysis sug-232 
gested two distinct branches, Figure 1. Branch I contained just 6 strains and appears to represent 233 
a clade that is no longer observed, containing the seemingly older alleles ptxA5 and ptxP4. The 234 
two branches appear to have diversified approximately 2000 years ago representing either two in-235 
dependent introductions into the human population, or that lineages representing genotypes inter-236 
mediate to the two branches have been lost. The genome reduction characteristic of B. pertussis 237 
occurred largely before diversification of the lineages as two reference strains, one from each line-238 
age, shared 72% of pseudogenes with the inactivating mutations being identical between the two 239 
strains. 240 
 241 
A potential role for vaccination in shaping the B. pertussis population is evident from these anal-242 
yses. Most recent isolates are contained in a lineage, IIb, that arose prior to the introduction of 243 
vaccination but which has diversified since its introduction and this is associated with the rise of the 244 
ptxA1 allele, Figure 1. Vaccination might be expected to reduce diversity as many lineages would 245 
be eradicated. However, if a particular genotype exhibits a degree of vaccine escape, it would ex-246 
pand and diversify in areas of vaccination. A second wave of diversification arose from the emer-247 
gence and subsequent expansion of the lineage carrying ptxP3, discussed above. The introduction 248 
of ACV coincides with the decline of the ptxA1 carrying lineage followed by further expansion of 249 
the ptxP3 lineage by the acquisition of the fim3-2 allele. These data do fit with the theory of vac-250 
cines promoting the expansion and subsequent diversification of particular genotypes, presumably 251 
those less controlled than others by vaccine-induced immunity. However, definitive evidence that 252 
these strains do resist vaccine-induced immunity to a greater degree than other lineages is cur-253 
rently lacking. 254 
 255 
This seminal study included strains isolated during and subsequent to the introduction of ACVs but 256 
only 3 isolates were more recent than 2008. A more recent study built on these observations, 257 
again utilising whole genome sequencing but with a focus on strains isolated during the UK 2012 258 
Pertussis outbreak (Sealey, et al. 2014). This revealed that this large outbreak was polyclonal in 259 
nature, with numerous closely related, but distinct clones contributing to it. Importantly, there was 260 
no novel genotype identified among the outbreak isolates. Indeed the isolates were very closely 261 
related to those observed among periods when the incidence of Pertussis was low. Thus, genomic 262 
data strongly suggests that resurgence is not the result of a particular genetic change producing a 263 
hypervirulent clone. 264 
 265 
The genome sequences generated in these studies allowed calculation of SNP densities for differ-266 
ent categories of genes, changes in these frequencies over time and correlation of changes with 267 
implementation of WCV or ACV. Bart et al observed that genes categorised as either ‘virulence’ or 268 
‘transport and binding’ genes contained a SNP density higher than the genome average (Bart, et 269 
al. 2013). This could be due to these genes’ products being exposed to the bacteria’s environment 270 
and thus subject to e.g. immunity-mediated selection pressure. ACVs, containing just Prn, Ptx, 271 
Fim2, Fim3 and FHA, would be expected to induce selection pressure against just these five anti-272 
gens. Sealey et al calculated that, compared to other genes encoding putative surface proteins, 273 
the genes encoding the ACV antigens had significantly higher SNP densities. Moreover, this was 274 
the case prior to the introduction of Pertussis vaccines but the SNP density in ACV antigen encod-275 
ing genes is significantly higher among strains isolated since the introduction of ACVs compared to 276 
those isolated prior to this (Sealey, et al. 2014). This is consistent with the ACV antigen encoding 277 
genes being under selection pressure prior to vaccination. These proteins are highly immunogenic 278 
(hence being selected for vaccination) and infection would generate immunity directed against 279 
them. However, there is a clear signal that their rate of evolution has increased recently, and this 280 
could be due to ACV-induced immunity focusing on these few proteins. This raises obvious con-281 
cerns about accelerated evolution of B. pertussis and the effect of this on the ability of ACV to con-282 
trol Pertussis. 283 
 284 
6 
These studies represent a step change in the analysis of B. pertussis and importantly establish 285 
genome sequencing as a central approach in this area. They have revealed unprecedented detail 286 
of B. pertussis diversity and evolution. Their findings support the hypotheses that vaccination cre-287 
ates selection pressure on B. pertussis and that certain genotypes have fitness advantages under 288 
this pressure. The consequence of this is presumably that B. pertussis is evolving towards ever 289 
increasing vaccine escape, with all of the public health concerns that this would entail. However, 290 
the data raise as many questions as they answer, and answering these questions is going to be 291 
critical to understanding the current picture of resurgence and perhaps more importantly, the likely 292 
trajectory of Pertussis incidence in future years. 293 
 294 
For example, if vaccination creates selection pressure on ACV antigen genes, why is greater varia-295 
tion not observed? Although genomic analyses have identified changes in vaccine antigen gene 296 
alleles over time, and shown that these genes are faster evolving than other surface protein encod-297 
ing genes, the level of variation appears to be still very low. 298 
 299 
For ptxA, just eight alleles were observed world wide, including two silent mutations and thus just 300 
six putative protein variants are known, with just one or two amino acid differences between them. 301 
Furthermore, ptxA1 and ptxA2 were found in 96% of the strains (Bart, et al. 2013), including all of 302 
the recent UK isolates analysed (Sealey, et al. 2014). Five alleles, with four putative protein vari-303 
ants were observed for fim3 (Bart, et al. 2013). Just two alleles are known for fim2, involving just a 304 
single amino acid change. FHA is not included in most analyses as this large gene (approximately 305 
10.8kb) contains numerous repeat regions making mapping of short read data problematic. Inter-306 
estingly, 14 alleles of the relatively short ptxP region were observed (Bart, et al. 2013) suggesting 307 
that sequence variation in B. pertussis does occur, although clearly the selection pressure must be 308 
different for this character compared to structural genes. 309 
 310 
Compared to the very limited variation displayed by the other ACV antigens, the situation regarding 311 
Prn is different. In the global study by Bart et al, twelve alleles gave rise to 11 putative protein vari-312 
ants, although just 3 alleles were found in 92% of strains (Bart, et al. 2013). Unlike the other ACV 313 
antigens, variation in prn occurred mainly through variation in the number of repeats. This is per-314 
haps a reversible process although the frequency at which repeat lengths might vary is unclear. Of 315 
particular importance is that very recently in several countries experiencing resurgence there has 316 
been a dramatic rise in the incidence of strains not expressing Prn, although with notable variation 317 
between countries.  For example, in Finland, in a study of 76 clinical isolates, only 2 were pertac-318 
tin-deficient by ELISA, both isolates came from infants who had received the acellular vaccine 319 
(Barkoff, et al. 2012: 1703-4). In Australia and Japan studies suggest that the proportion of pertac-320 
tin negative strains in circulation is higher, with 27% of 121 strains tested in Japan (Otsuka, et al. 321 
2012: e31985)and 30% of 320 strains tested in Australia negative for pertactin expression (Lam, et 322 
al. 2014: 626-33). In the US the prevalence of pertactin-deficient strains appears to be higher still, 323 
topping 50% of currently circulating strains (Pawloski, et al. 2014: 119-25). Prn deficiency arises by 324 
a number of mechanisms: gene deletions, SNPs creating internal stop codons and promoter inver-325 
sion, but the most widespread mechanism is mutation by insertion of IS481 (Pawloski, et al. 2014: 326 
119-25). Interestingly, Prn-deficiency was not observed among the global collection analysed by 327 
Bart et al (Bart, et al. 2013) of strains predominantly from 2008 or earlier, highlighting that the 328 
spread of these strains is a very recent occurrence. The rise in incidence of Prn-deficient strains, 329 
seemingly mainly in countries using ACVs, has been taken as a rare example of evidence for the 330 
selective pressure exerted by ACV-induced immunity. While there has been no reported difference 331 
in clinical presentation of disease between those infected with a strain of B. pertussis expressing 332 
pertactin and a pertactin-deficient strain, the likelihood of having reported disease caused by a per-333 
tactin-deficient isolate compared with one expressing pertactin is greater in people who have re-334 
ceived the full course of pertussis vaccines, suggesting a selective advantage for pertactin-335 
deficiency in areas where coverage by ACV is high (Martin, et al. 2015: 223-7). Furthermore, using 336 
a mouse model it was shown that pertactin deficiency confers a fitness advantage in an ACV-337 
vaccinated host (Hegerle, et al. 2014: 6597-600). Naïve or ACV-vaccinated mice were infected 338 
with Prn-expressing or Prn-deficient strains. Naïve mice were colonized to the same levels regard-339 
less of Prn expression status, which is different to some previous reports (van Gent, et al. 2011: 340 
7 
e18014). However, Prn-expressing strains were cleared more rapidly from vaccinated mice com-341 
pared to the Prn-deficient strains, implying that Prn-deficiency is a fitness advantage in ACV-342 
vaccinated hosts (Hegerle, et al. 2014: 6597-600). It should be noted that the Prn-expressing and 343 
Prn-deficient strains very likely had other genetic differences, and thus to precisely identify the ef-344 
fect of Prn-deficiency, comparisons between WT and an isogenic Prn-deficient strain, or a naturally 345 
occurring Prn-deficient strain and one in which Prn expression has been reinstated, in ACV-346 
vaccinated hosts should be made. 347 
 348 
Thus, there appears to be striking differences between antigens in the effects of any ACV-349 
mediated selection pressure. It is clear that Prn-deficient strains must be able to infect people and 350 
transmit between them, and as most isolates are from clinical cases they appear to be virulent in 351 
terms of causing disease. Thus, Prn must not be required for these processes. It is possible that 352 
the other antigens are required, preventing the establishment of strains deficient for any of them. 353 
However, it is harder to envisage that greater levels of polymorphism are not tolerated in either of 354 
Ptx, Fim2 or Fim3. 355 
 356 
In particular, B. pertussis appears to be restricted to a single niche, the human nasopharynx. Many 357 
pathogens with similar restricted niches have much higher levels of variation within their popula-358 
tions than does B. pertussis. Even discounting the effect of vaccination, for continued circulation 359 
between hosts that have prior exposure to the pathogen there is likely selection pressure to vary in 360 
order to escape the immunity arising from previous exposure. Thus, other human restricted patho-361 
gens, for example Neisseria meningitidis and Streptococcus pneumoniae display extensive anti-362 
genic variation and exist as different clades with distinct gene repertoires. A similar scenario would 363 
appear to exist for B. pertussis. Does the small number of mutations observed in B. pertussis gen-364 
erate sufficient diversity for continuous circulation among its human hosts? Testing this is a very 365 
difficult task. Generating strains carrying individual SNPs to enable the effect of specific mutations 366 
to be analysed is feasible. However, such studies have been hindered by the lack of suitable mod-367 
els of disease and transmission. The infant baboon model does enable study of these aspects but 368 
experiments with these hosts are limited to low numbers of animals and subtle effects may be 369 
missed due to this. In vitro assays, for example measuring the effect of individual SNPs on recog-370 
nition of strains by antibodies in vaccine-immune sera or stimulation by of T cells from vaccinated 371 
individuals, have the capacity to be high throughput enabling the testing of many combinations of 372 
SNPs and sera. However, although both antibodies and T cells are likely to be important for pro-373 
tective immunity, definitive correlates of protection have yet to be identified making it difficult to ex-374 
trapolate results from in vitro assays to the in vivo situation. 375 
 376 
Alternatively, is it possible that host immunity is not a strong selective pressure on B. pertussis? A 377 
number of recent studies have indicated that both natural infection induced- and vaccine-induced 378 
immunity is somewhat short-lived, waning by adolescence, if not earlier. For vaccine-mediated 379 
immunity in particular to be a strong selective pressure on B. pertussis, pre-adolescent hosts must 380 
be a major part of the ecology of B. pertussis. Little is known about the circulation of B. pertussis in 381 
the general population. Very few studies have monitored B. pertussis outside of people presenting 382 
with cough symptoms. It is reasoned that anti-PT antibody titres above a certain threshold in peo-383 
ple with no recent history of cough illness or vaccination are an indication of recent infection 384 
by/exposure to B. pertussis. Seroprevalence levels vary widely between studies. However, many 385 
suggest that many more people encounter B. pertussis than present with disease, for example 386 
(Huygen, et al. 2014: 724-8, Ronn, et al. 2014: 729-37, Scott, et al. 2015: 333-8). In this case it is 387 
likely that B. pertussis is endemic in the human population but causes disease in only a proportion 388 
of those carrying the organism, with infants being particularly susceptible to disease in its most se-389 
rious form. If asymptomatic infection in ‘healthy’ people is the major B. pertussis-human interaction 390 
then it is critical to understand the nature of that interaction, particularly the host response, to de-391 
termine possible immune-mediated selection pressures that might be exerted on the bacteria. In 392 
this regard, it is also important to isolate bacteria from cases of asymptomatic carriage. To date, all 393 
isolates examined have been recovered from cases of Pertussis, or at least Pertussis-like cough 394 
illness. It is important to determine that these isolates are representative of the larger B. pertussis 395 
population and that disease-causing B. pertussis are not some separate lineage, although there is 396 
no evidence that this is the case. 397 
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 398 
An additional scenario is that B. pertussis does exhibit variation, but this is not via variation in DNA 399 
content or DNA sequence per se. Genomic analyses revealed variability among strains in the dele-400 
tions that they carried (Bouchez, et al. 2008: e2437, Kallonen, et al. 2011: 2034-42, King, et al. 401 
2010: 64). While a number of deletions appear to be common to many strains, numerous strains 402 
carry either strain-specific deletions, or deletions shared by just a few strains (for example, 403 
(Sealey, et al. 2014)). It has been assumed that deleted regions contain genes not required for B. 404 
pertussis’s human-adapted niche, and thus that deletions are mainly neutral in terms of fitness, but 405 
this has not been investigated. In addition, the first genome sequence of B. pertussis Tohama I re-406 
vealed the role of IS481-mediated recombination not only in generating deletions but also in intra-407 
genomic recombination (Parkhill, et al. 2003: 32-40). Little is known about conservation or variabil-408 
ity of IS481 insertions among strains, and thus the potential for variation in recombination and the 409 
resulting genome arrangement among them. Although genome sequences have been generated 410 
for hundreds of strains, this was largely using Illumina, short read sequencing. These sequence 411 
reads are too short to span the 1kb IS481 repeats and thus genome assembly programmes are 412 
confounded by the repeats, producing assemblies comprised of over 200 contigs, most of which 413 
likely terminate at an IS481 element. Thus, although the DNA content of each strain and the se-414 
quence of this content is identified by this approach, it is not possible to produce closed, ordered 415 
genome sequences from these data. The advent of long-read sequence platforms, including the 416 
PacBio RS system and potentially the Oxford Nanopore technology, enables the generation of 417 
reads that encompass IS repeats and allow long range scaffolds to be assembled and closed ge-418 
nome sequences to be achieved (Liao, et al. 2015: 8747). The closed genome sequences of two 419 
Dutch strains assembled in this way identified three large inversions when comparing the two se-420 
quences, demonstrating different genome arrangements between the two strains (Bart, et al. 421 
2014). Comparison of additional strains for which closed genome sequences have been generated 422 
identifies a greater level of genome arrangement variation Figure 2 (Preston unpublished). In this 423 
alignment based analysis, numerous inversions and translocations are apparent. That such a 424 
range of genome arrangements was found among the limited number of strains analysed suggests 425 
that the potential for genome arrangement variation among B. pertussis strains could be extensive. 426 
 427 
Genome arrangement affects several factors thought to be determinants of gene expression (for 428 
example see (Couturier and Rocha 2006: 1506-18): distance of a gene from the origin/terminus of 429 
DNA replication, the strand on which the gene is encoded (leading or lagging), transcriptional or-430 
ganisation (e.g. operon structure, orientation to neighbours), the distance of transcriptional regula-431 
tors from their target genes, the organisation of non-coding RNAs and the location of genes in rela-432 
tion to transcriptionally active IS elements. Even genetically identical cells can exhibit phenotypic 433 
variations arising from stochasticity in gene expression. Extrinsic noise, arising from e.g. fluctua-434 
tions in cellular components can give rise to fluctuations in gene expression (Elowitz, et al. 2002: 435 
1183-6, Raser and O'Shea 2005: 2010-3). Variation in genome arrangement is likely to generate 436 
different internal environments between strains, affect gene expression and lead to variation in 437 
phenotype. Thus, it is possible that variation in genome arrangement is generates diversity among 438 
B. pertussis, but this remains speculation at present. 439 
 440 
The difficulty will be devising approaches to investigate diversity among strains. Many of the de-441 
tected variations are within uncharacterised genome regions, meaning it is not clear what pheno-442 
typic traits might vary, and that it is unlikely the necessary assays exist. A major obstacle is that 443 
subtle variations likely lead to subtle variations in phenotypes. Studies in traditional models such 444 
as murine or baboons can accommodate only small numbers of hosts meaning that the power to 445 
detect minor differences is lacking, although at the population level (of hosts) subtle variations may 446 
be significant. If variation in genome arrangement does affect gene expression levels then they are 447 
detectable using gene expression profiling (e.g. RNAseq, see below) but the difficulty then be-448 
comes interpretation of these complex datasets and still leads to the same problem of testing hy-449 
potheses raised by such studies regarding phenotypic variation. 450 
 451 
Outlook 452 
The resurgence of Pertussis has led to renewed interest in B. pertussis. It is evident that our un-453 
derstanding of the infection biology of this bacterium, at both the level of an individual host, and at 454 
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the population level is surprisingly poor. The advent of vaccination appeared to remove the need to 455 
study B. pertussis as a pressing infectious disease issue and while very elegant work has focused 456 
on the biology of the major ‘virulence factors’, it is clear that our knowledge does not explain suffi-457 
ciently what is happening at present. 458 
 459 
Clearly it is very important to decipher the precise mechanisms of immunity arising from infection 460 
and vaccination (both WCV and ACV). This will very likely shed light on the role of the switch to 461 
ACV in resurgence. This work will also define precise immune correlates of protection which will 462 
greatly aid developments involving changes to vaccine schedules or the development of enhanced 463 
or new vaccines. It is also important to understand whether changes to B. pertussis observed over 464 
the last decades is adaptation to host factors, particularly vaccine-induced immunity, and to be 465 
able to extrapolate this to the future to enable policy decisions to be made regarding future control 466 
measures for Pertussis. In turn this will involve also a much deeper understanding of the epidemi-467 
ology of Pertussis, as this is required to target control measures to the right members of the popu-468 
lation to achieve the best overall protection possible. Genomics-based approaches will play a key 469 
role in all of these areas. 470 
 471 
Monitoring further changes in B. pertussis is clearly important for identifying and understanding 472 
genetic changes that might herald further changes in behaviour and further adaptations, whether in 473 
response to vaccination or otherwise. It is clear that fine scale resolution between strains, and cap-474 
ture of all of the genetic variation among B. pertussis, requires whole genome sequencing ap-475 
proaches. The high throughput capacity, decreasing cost and increasing accessibility of next gen-476 
eration DNA sequencers to researchers and reference labs means that WGS approaches will likely 477 
become routine for surveillance of B. pertussis, an approach that will still enable traditional charac-478 
ters such as MVLA type and allele types to be ascertained. However, it is worth considering that by 479 
far and away the most common NGS platform used is Illumina, based on short read sequencing. If 480 
ordered, assembled genome sequences are required to fully appreciate B. pertussis diversity then 481 
longer read technologies will need to be considered incorporated into this surveillance. The issue 482 
then arises of how to utilise such data into a useable epidemiological framework. Would isolates 483 
that differ by just a single SNP, or those that have no SNP differences but differ by a translocation 484 
be regarded as different strains, or what level of variation would be considered a different lineage? 485 
If the aim of this surveillance is to identify changes that impact on infection then the same problem 486 
arises as discussed above, i.e. the difficulty in deciphering genetic changes in terms of assayable 487 
phenotypes, and the lack of models that might detect subtle changes. A further challenge to con-488 
tinued surveillance of B. pertussis is the increasing use of non-culture based diagnosis, in particu-489 
lar PCR and serology. These approaches have the great advantage of being relatively non-490 
invasive, and fast, compared to the nasopharyngeal swabs required for culture-based diagnosis. 491 
However, it is crucial that collection of B. pertussis cultures is continued in order to be able to 492 
monitor the pathogen, detect further changes in it and for studies that investigate the effects of any 493 
changes. 494 
 495 
The resurgence of Pertussis has given renewed impetus to the need to better understand B. per-496 
tussis infection biology, including the host response. Despite the deciphering of the genetic code of 497 
B. pertussis over 10 years ago, the number of functionally characterised loci in B. pertussis re-498 
mains remarkably small. These loci include those coding for adhesins, toxins, and other factors 499 
important for infection but these represent a very small fraction of the gene content of B. pertussis. 500 
Functional genomics offers a means to move away from traditional reductionist approaches of 501 
studying individual gene systems at a time towards systems level analyses of B. pertussis during 502 
infection. Transcriptional profiling is a powerful approach for genome-wide monitoring of active 503 
processes, and changes in gene expression levels are a valuable indicator of those processes 504 
whose activity varies e.g. during the course of an infection, or dependent on the within-host site 505 
occupied. While transcriptional profiling is admittedly just a proxy for protein expression, the rela-506 
tively tight correlation in bacteria between transcriptional and translational levels makes it a very 507 
useful readout. Thus, transcriptional profiling of bacteria in different host niches within the respira-508 
tory tract, over time, during infection will shed new light on the activity of characterised systems, 509 
and identify novel systems that are tightly linked to the progression of Pertussis from initial coloni-510 
sation to symptomatic disease and transmission to new hosts. The infant baboon model is likely to 511 
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be central to these advances. Applying this approach to the study of host responses to infection 512 
will be valuable to defining the responses of host cells to infection and immunisation and in turn for 513 
deciphering the mechanisms operating for each. This will be critical to not only understanding the 514 
current situation, but also in the design of potential novel B. pertussis vaccines, the need for which 515 
has been hotly debated (Poolman 2014: 1159-62). 516 
 517 
The resurgence of Pertussis in countries using the ACV has raised serious public health concerns. 518 
It is not yet clear whether resurgence is temporary or if recent trends signal a sustained period of 519 
(relatively) high levels of disease. There is strong evidence implicating the use of ACVs as a con-520 
tributing factor to resurgence. A number of solutions have been discussed including various pro-521 
grammes of additional boosters using ACVs, the inclusion of additional antigens or adjuvants to 522 
the ACV as well as possible development of novel Pertussis vaccines. In addition, evidence for B. 523 
pertussis evolution under the influence of vaccine-mediated immunity means that the pathogen 524 
side of the equation must be factored in to these scenarios. From this, it is clear that our current 525 
understanding of B. pertussis infection and immunity is insufficient to allow a solution to be devised 526 
with any certainty of its success. Remediation of this knowledge gap will be heavily dependent on 527 
the use of genomics-based approaches. 528 
 529 
References. 530 
Barkoff AM, Mertsola J, Guillot S et al. Appearance of Bordetella pertussis strains not expressing 531 
the vaccine antigen pertactin in Finland. Clinical and vaccine immunology : CVI 2012;19: 532 
1703-4. 533 
Bart M, Harris S, Advani A. Global Population Structure and Evolution of Bordetella Pertussis and 534 
their Relationship with Vaccination. submitted 2013. 535 
Bart MJ, Zeddeman A, van der Heide HG et al. Complete Genome Sequences of Bordetella 536 
pertussis Isolates B1917 and B1920, Representing Two Predominant Global Lineages. 537 
Genome announcements 2014;2. 538 
Bouchez V, Caro V, Levillain E et al. Genomic content of Bordetella pertussis clinical isolates 539 
circulating in areas of intensive children vaccination. PloS one 2008;3: e2437. 540 
Burns DL, Meade BD, Messionnier NE. Pertussis Resurgence: Perspectives From the Working 541 
Group Meeting on Pertussis on the Causes, Possible Paths Forward, and Gaps in Our 542 
Knowledge. Journal of Infectious Diseases 2014;209: S32-S5. 543 
Cherry JD. Pertussis - the Trials and Tribulations Of Old and New Pertussis Vaccines. Vaccine 544 
1992;10: 1033-8. 545 
Cherry JD. Acellular pertussis vaccines-a solution to the pertussis problem. The Journal of 546 
infectious diseases 1993;168: 21-4. 547 
Cherry JD. Historical Review Of Pertussis and the Classical Vaccine. Journal Of Infectious 548 
Diseases 1996;174: S 259-S 63. 549 
Couturier E, Rocha EP. Replication-associated gene dosage effects shape the genomes of fast-550 
growing bacteria but only for transcription and translation genes. Molecular microbiology 551 
2006;59: 1506-18. 552 
Darling AC, Mau B, Blattner FR et al. Mauve: multiple alignment of conserved genomic sequence 553 
with rearrangements. Genome research 2004;14: 1394-403. 554 
Diavatopoulos DA, Cummings CA, Schouls LM et al. Bordetella pertussis, the Causative Agent of 555 
Whooping Cough, Evolved from a Distinct, Human-Associated Lineage of B. 556 
bronchiseptica. PLoS pathogens 2005;1: e45. 557 
Elowitz MB, Levine AJ, Siggia ED et al. Stochastic gene expression in a single cell. Science 558 
2002;297: 1183-6. 559 
Harvill ET, Goodfield LL, Ivanov Y et al. Genome Sequences of Nine Bordetella holmesii Strains 560 
Isolated in the United States. Genome announcements 2014;2. 561 
Hegerle N, Dore G, Guiso N. Pertactin deficient Bordetella pertussis present a better fitness in 562 
mice immunized with an acellular pertussis vaccine. Vaccine 2014;32: 6597-600. 563 
Huygen K, Rodeghiero C, Govaerts D et al. Bordetella pertussis seroprevalence in Belgian adults 564 
aged 20-39 years, 2012. Epidemiology and infection 2014;142: 724-8. 565 
Kallonen T, Grondahl-Yli-Hannuksela K, Elomaa A et al. Differences in the genomic content of 566 
Bordetella pertussis isolates before and after introduction of pertussis vaccines in four 567 
11 
European countries. Infection, genetics and evolution : journal of molecular epidemiology 568 
and evolutionary genetics in infectious diseases 2011;11: 2034-42. 569 
King AJ, van der Lee S, Mohangoo A et al. Genome-wide gene expression analysis of Bordetella 570 
pertussis isolates associated with a resurgence in pertussis: elucidation of factors involved 571 
in the increased fitness of epidemic strains. PloS one 2013;8: e66150. 572 
King AJ, van Gorkom T, van der Heide HG et al. Changes in the genomic content of circulating 573 
Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: 574 
adaptive evolution or drift? BMC genomics 2010;11: 64. 575 
Kurniawan J, Maharjan RP, Chan WF et al. Bordetella pertussis clones identified by multilocus 576 
variable-number tandem-repeat analysis. Emerging infectious diseases 2010;16: 297-300. 577 
Lam C, Octavia S, Bahrame Z et al. Selection and emergence of pertussis toxin promoter ptxP3 578 
allele in the evolution of Bordetella pertussis. Infection, genetics and evolution : journal of 579 
molecular epidemiology and evolutionary genetics in infectious diseases 2012;12: 492-5. 580 
Lam C, Octavia S, Ricafort L et al. Rapid increase in pertactin-deficient Bordetella pertussis 581 
isolates, Australia. Emerging infectious diseases 2014;20: 626-33. 582 
Lapin JH. Whooping cough. Springfield, Ill: Charles C. Thomas, 1943. 583 
Liao YC, Lin SH, Lin HH. Completing bacterial genome assemblies: strategy and performance 584 
comparisons. Scientific reports 2015;5: 8747. 585 
Litt DJ, Neal SE, Fry NK. Changes in genetic diversity of the Bordetella pertussis population in the 586 
United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a 587 
single dominant clonal type. Journal of clinical microbiology 2009;47: 680-8. 588 
Lugauer S, Heininger U, Cherry JD et al. Long-term clinical effectiveness of an acellular pertussis 589 
component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002;161: 590 
142-6. 591 
Martin SW, Pawloski L, Williams M et al. Pertactin-negative Bordetella pertussis strains: evidence 592 
for a possible selective advantage. Clinical infectious diseases : an official publication of the 593 
Infectious Diseases Society of America 2015;60: 223-7. 594 
Mira A, Pushker R, Rodriguez-Valera F. The Neolithic revolution of bacterial genomes. Trends in 595 
microbiology 2006;14: 200-6. 596 
Mooi FR. Bordetella pertussis and vaccination: the persistence of a genetically monomorphic 597 
pathogen. Infection, genetics and evolution : journal of molecular epidemiology and 598 
evolutionary genetics in infectious diseases 2010;10: 36-49. 599 
Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen 600 
adaptation - two sides of the same coin. Epidemiology and infection 2014;142: 685-94. 601 
Mooi FR, van Loo IH, van Gent M et al. Bordetella pertussis strains with increased toxin production 602 
associated with pertussis resurgence. Emerging infectious diseases 2009;15: 1206-13. 603 
Otsuka N, Han HJ, Toyoizumi-Ajisaka H et al. Prevalence and genetic characterization of 604 
pertactin-deficient Bordetella pertussis in Japan. PloS one 2012;7: e31985. 605 
Parkhill J, Sebaihia M, Preston A et al. Comparative analysis of the genome sequences of 606 
Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 607 
2003;35: 32-40. 608 
Pawloski LC, Queenan AM, Cassiday PK et al. Prevalence and molecular characterization of 609 
pertactin-deficient Bordetella pertussis in the United States. Clinical and vaccine 610 
immunology : CVI 2014;21: 119-25. 611 
Poolman JT. Shortcomings of pertussis vaccines: why we need a third generation vaccine. Expert 612 
review of vaccines 2014;13: 1159-62. 613 
Preston A, Parkhill J, Maskell DJ. The Bordetellae: lessons from genomics. Nat Rev Microbiol 614 
2004;2: 379-90. 615 
Raser JM, O'Shea EK. Noise in gene expression: origins, consequences, and control. Science 616 
2005;309: 2010-3. 617 
Rendi-Wagner P, Kundi M, Mikolasek A et al. Hospital-based active surveillance of childhood 618 
pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of 619 
whole-cell and acellular vaccine. Vaccine 2006;24: 5960-5. 620 
Ronn PF, Dalby T, Simonsen J et al. Seroepidemiology of pertussis in a cross-sectional study of 621 
an adult general population in Denmark. Epidemiology and infection 2014;142: 729-37. 622 
12 
Ross PJ, Sutton CE, Higgins S et al. Relative contribution of Th1 and Th17 cells in adaptive 623 
immunity to Bordetella pertussis: towards the rational design of an improved acellular 624 
pertussis vaccine. PLoS pathogens 2013;9: e1003264. 625 
Scott S, van der Sande M, Faye-Joof T et al. Seroprevalence of pertussis in the Gambia: evidence 626 
for continued circulation of bordetella pertussis despite high vaccination rates. The 627 
Pediatric infectious disease journal 2015;34: 333-8. 628 
Sealey KL, Harris SR, Fry NK et al. Genomic Analysis of Isolates From the United Kingdom 2012 629 
Pertussis Outbreak Reveals That Vaccine Antigen Genes Are Unusually Fast Evolving. The 630 
Journal of infectious diseases 2014, DOI 10.1093/infdis/jiu665. 631 
van Gent M, Bart MJ, van der Heide HG et al. Small mutations in Bordetella pertussis are 632 
associated with selective sweeps. PloS one 2012;7: e46407. 633 
van Gent M, Heuvelman CJ, van der Heide HG et al. Analysis of Bordetella pertussis clinical 634 
isolates circulating in European countries during the period 1998-2012. European journal of 635 
clinical microbiology & infectious diseases : official publication of the European Society of 636 
Clinical Microbiology 2015;34: 821-30. 637 
van Gent M, van Loo IH, Heuvelman KJ et al. Studies on Prn variation in the mouse model and 638 
comparison with epidemiological data. PloS one 2011;6: e18014. 639 
Warfel JM, Beren J, Kelly VK et al. Nonhuman primate model of pertussis. Infection and immunity 640 
2012;80: 1530-6. 641 
Warfel JM, Edwards KM. Pertussis vaccines and the challenge of inducing durable immunity. Curr 642 
Opin Immunol 2015;35: 48-54. 643 
Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail 644 
to prevent infection and transmission in a nonhuman primate model. Proceedings of the 645 
National Academy of Sciences of the United States of America 2013, DOI 646 
10.1073/pnas.1314688110. 647 
WHO. Global and regional immunization profile volume 2015, 2014. 648 
Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis 649 
vaccination in preadolescents in a North American outbreak. Clinical infectious diseases : 650 
an official publication of the Infectious Diseases Society of America 2012;54: 1730-5. 651 
 652 
Figure Legends. 653 
 654 
Figure 1. 655 
Phylogeny of a global collection of B. pertussis strains depicting the two lineages denoted as 656 
Branch I and II. The approximate periods in which WCV were used widely and in which ACV were 657 
introduced are indicated. The appearance of prominent alleles is indicated on the tree and the ACV 658 
antigen allele profile of strains is colour-coded. Green circles indicate the two reference strans To-659 
hama I (T) and 18323; black circles indicate two US vaccine strains (B308, branch I and B310, 660 
branch II). Reproduced from (Bart, et al. 2013) with permission.  661 
 662 
Figure 2. 663 
Variation in genome arrangement among B. pertussis strains. Alignment of closed, ordered ge-664 
nome sequences of multiple B. pertussis strains was performed using Mauve (Darling, et al. 2004: 665 
1394-403). This displays aligned genomes as locally colinear blocks (LCBs); conserved segments 666 
of genomes that are free from internal rearrangements. The B. pertussis Tohama I genome se-667 
quence (Parkhill, et al. 2003: 32-40) is displayed as the reference sequence. In other strains, an 668 
LCB that is located at a different point in the genome indicates a translocation relative to Tohama I. 669 
An LCB below the central black line indicates an inversion event relative to Tohama I. The align-670 
ment also displays relative DNA sequence conservation where major deletions are shown as white 671 
sections within LCBs. To note here are that each strain contains rearrangements relative to To-672 
hama I and each other. Strains B1920 and B1917 are Dutch strains isolated in 2000 representing 673 
the major ptxP1 and ptxP3 lineages respectively (Bart, et al. 2014). UK strains have been de-674 
scribed previously (Sealey, et al. 2014) and were isolated in 1920 (UK1), 1942 (UK2), 2006 675 
(UK16), 2011 (UK51) and 2012 (UK69). The closed genome sequences were generated using 676 
both PacBio and Illumina sequencing (Preston, unpub.). D420 is a US isolate (Warfel, et al. 2012: 677 
1530-6). 678 
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